Cart
sales@molnova.com
O-Methylbroussochalcone B
CAS No. 20784-60-5
O-Methylbroussochalcone B( —— )
Catalog No. M20257 CAS No. 20784-60-5
4'-O-Methylbavachalcone is isolated from Psoralea corylifolia inhibits severe acute respiratory syndrome coronavirus (SARS-CoV) papain-like protease (PLpro) activity (IC50: 10.1 μM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 95 | In Stock |
|
| 5MG | 80 | In Stock |
|
| 10MG | 140 | In Stock |
|
| 25MG | 236 | In Stock |
|
| 50MG | 343 | In Stock |
|
| 100MG | 505 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameO-Methylbroussochalcone B
-
NoteResearch use only, not for human use.
-
Brief Description4'-O-Methylbavachalcone is isolated from Psoralea corylifolia inhibits severe acute respiratory syndrome coronavirus (SARS-CoV) papain-like protease (PLpro) activity (IC50: 10.1 μM).
-
Description4'-O-Methylbavachalcone is isolated from Psoralea corylifolia inhibits severe acute respiratory syndrome coronavirus (SARS-CoV) papain-like protease (PLpro) activity (IC50: 10.1 μM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorPlpro
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number20784-60-5
-
Formula Weight338.4
-
Molecular FormulaC21H22O4
-
Purity>98% (HPLC)
-
SolubilityDMSO: Soluble
-
SMILESCOc1cc(O)c(cc1C\C=C(\C)C)C(=O)\C=C\c1ccc(O)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kim DW et al. Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia. J Enzyme Inhib Med Chem. 2014 Feb;29(1):59-63.
molnova catalog
related products
-
TPPU
TPPU is a potent inhibitor of both human and mouse sEH (IC50 of 3.7 and 2.8 nM respectively).
-
Somatostatin-14 (red...
Somatostatin-14 (reduced)
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
